Catharie C. Nass
American Red Cross
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Catharie C. Nass.
Transfusion | 2006
George B. Schreiber; Karen S. Schlumpf; Simone A. Glynn; David Wright; Yongling Tu; Melissa King; Martha J. Higgins; Debra Kessler; Ronald O. Gilcher; Catharie C. Nass; Anne M. Guiltinan
BACKGROUND: To prevent donor loss and improve retention, it is important to understand the major deterrents to blood donation and to identify factors that can be effectively addressed by blood centers.
Transfusion | 1999
Helen E. Ownby; F. Kong; K. Watanabe; Yongling Tu; Catharie C. Nass
BACKGROUND: Efforts to provide a safe, adequate blood supply have been inhibited by persistent shortages attributed to a lack of motivation on the part of the general public and inefficiency in recruiting processes. This study examined whether frequency of donations and/or timing of subsequent donations by first‐time donors related to donor demographics.
Transfusion | 2007
Whitney R. Steele; George B. Schreiber; Anne M. Guiltinan; Catharie C. Nass; Simone A. Glynn; David Wright; Debra Kessler; Karen S. Schlumpf; Yongling Tu; James W. Smith; George Garratty
BACKGROUND: Blood donation can be described as a prosocial behavior, and donors often cite prosocial reasons such as altruism, empathy, or social responsibility for their willingness to donate. Previous studies have not quantitatively evaluated these characteristics in donors or examined how they relate to donation frequency.
Transfusion | 2003
Simone A. Glynn; Alan E. Williams; Catharie C. Nass; James Bethel; Debra Kessler; Edward P. Scott; Joy Fridey; Steven H. Kleinman; George B. Schreiber; Retrovirus Epidemiology Donor Study
BACKGROUND : The potential effectiveness of various donation incentive programs may vary by demographics, first‐time or repeat status, and collection site.
Emerging Infectious Diseases | 2004
Edward L. Murphy; Baoguang Wang; Ronald A. Sacher; Joy Fridey; James W. Smith; Catharie C. Nass; Bruce Newman; Helen E. Ownby; George Garratty; Sheila Hutching; George B. Schreiber
Human T-lymphotropic virus types I and II (HTLV-I and -II) cause myelopathy; HTLV-I, but not HTLV-II, causes adult T-cell leukemia. Whether HTLV-II is associated with other diseases is unknown. Using survival analysis, we studied medical history data from a prospective cohort of HTLV-I– and HTLV-II–infected and –uninfected blood donors, all HIV seronegative. A total of 152 HTLV-I, 387 HTLV-II, and 799 uninfected donors were enrolled and followed for a median of 4.4, 4.3, and 4.4 years, respectively. HTLV-II participants had significantly increased incidences of acute bronchitis (incidence ratio [IR] = 1.68), bladder or kidney infection (IR = 1.55), arthritis (IR = 2.66), and asthma (IR = 3.28), and a borderline increase in pneumonia (IR = 1.82, 95% confidence interval [CI] 0.98 to 3.38). HTLV-I participants had significantly increased incidences of bladder or kidney infection (IR = 1.82), and arthritis (IR = 2.84). We conclude that HTLV-II infection may inhibit immunologic responses to respiratory infections and that both HTLV-I and -II may induce inflammatory or autoimmune reactions.
The Journal of Infectious Diseases | 2005
Diana F. Roucoux; Baoguang Wang; Donna Smith; Catharie C. Nass; James W. Smith; Sheila Hutching; Bruce Newman; Tzong-Hae Lee; Daniel M. Chafets; Htlv Outcomes Study Investigators
BACKGROUND Cross-sectional studies support sexual transmission of human T lymphotropic virus (HTLV)-I/II; however, prospective incidence data, particularly for HTLV-II, are limited. METHODS A cohort of 85 HTLV-positive (30 with HTLV-I and 55 with HTLV-II) blood donors and their stable (>or=6 months) heterosexual sex partners were followed biannually over the course of a 10-year period. RESULTS Four of 85 initially seronegative sex partners of HTLV-I and -II carriers seroconverted, for an incidence rate (IR) of 0.6 transmissions/100 person-years (py) (95% confidence interval [CI], 0.2-1.6). This includes 2 HTLV-I transmissions/219 py (IR, 0.9 transmissions/100 py [95% CI, 0.1-3.3]) and 2 HTLV-II transmissions/411 py (IR, 0.5 transmissions/100 py [95% CI, 0.06-1.8]), with no significant difference by HTLV type. There were 2 male-to-female (IR, 1.2 transmissions/100 py [95% CI, 0.1-4.3]) and 2 female-to-male (IR, 0.4 transmissions/100 py [95% CI, 0.05-1.6) transmissions. HTLV-I or -II proviral load was 2 log10 lower in newly infected partners than in index positive partners who transmitted HTLV (P=.007). CONCLUSIONS The incidence of sexual transmission of HTLV-II may be similar to that of HTLV-I, and female-to-male transmission may play a more important role than previously thought. HTLV-I and -II proviral load may be lower in sexually acquired infection, because of a small infectious dose.
Transfusion | 1998
Ruth A. Thomson; James Bethel; Annie Lo; Helen E. Ownby; Catharie C. Nass; Alan E. Williams
BACKGROUND: There are obvious advantages to increasing donor retention. However, for reasons of blood safety, certain donors may, in fact, be more desirable to retain than others. “Safe” donors are defined as those who provided a blood donation that was negative on all laboratory screening tests and who subsequently reported no behavioral risks in response to an anonymous survey. This study identifies the most important factors affecting the intention of “safe” donors to provide another donation.
The Journal of Infectious Diseases | 1997
Edward L. Murphy; Simone A. Glynn; Joy Fridey; Ronald A. Sacher; James W. Smith; David Wright; Bruce Newman; Joan Gibble; Dannie I. Ameti; Catharie C. Nass; George B. Schreiber; George J. Nemo
Disease associations of human T lymphotropic virus types I and II (HTLV-I and -II) infection were studied in 154 HTLV-I-infected, 387 HTLV-II-infected, and 799 uninfected blood donors. Adjusted odds ratios (ORs) and 99% confidence intervals (CIs) were derived from logistic regression models controlling for demographics and relevant confounders. All subjects were human immunodeficiency virus type 1-seronegative. HTLV-II was significantly associated with a history of pneumonia (OR, 2.6; 99% CI, 1.2-5.3), minor fungal infection (OR, 2.9; 99% CI, 1.2-7.1), and bladder or kidney infection (OR, 1.6; 99% CI, 1.0-2.5) within the past 5 years and with a lifetime history of tuberculosis (OR, 3.9; 99% CI, 1.3-11.6) and arthritis (OR, 1.8; 99% CI, 1.2-2.9). Lymphadenopathy (> or =1 cm) was associated with both HTLV-I (OR, 6.6; 99% CI, 2.2-19.2) and HTLV-II (OR, 2.8; 99% CI, 1.1-7.1) infection, although no case of adult T cell leukemia/lymphoma was diagnosed. Urinary urgency and gait disturbance were associated with both viruses. This new finding of increased prevalence of a variety of infections in HTLV-II-positive donors suggests immunologic impairment.
Transfusion | 2005
Ana M. Sanchez; George B. Schreiber; Catharie C. Nass; Simone A. Glynn; Debra Kessler; Nora V. Hirschler; Joy Fridey; James Bethel; Edward L. Murphy; Michael P. Busch
BACKGROUND: Men who have had sex with men (MSM) since 1977 are permanently deferred from donating blood. Excluding only men who engaged in male‐to‐male sex within either the prior 12 months or 5 years has been proposed. Little is known about infectious disease risks of MSM who donate blood.
The Journal of Infectious Diseases | 1999
Edward L. Murphy; Kevin Watanabe; Catharie C. Nass; Helen E. Ownby; Alan E. Williams; George J. Nemo
The demographic and geographic determinants of human T lymphotropic virus types I and II (HTLV-I and -II) are not well defined in the United States. Antibodies to HTLV-I and -II were measured in 1.7 million donors at five US blood centers during 1991-1995. Among those tested, 156 (9.1/10(5)) were HTLV-I seropositive and 384 (22.3/10(5)) were HTLV-II seropositive. In contrast to monotonously increasing age-specific HTLV-I seroprevalence, HTLV-II prevalence rose until age 40-49 years and declined thereafter, suggesting a birth cohort effect. HTLV-II infection was independently associated with an age of 40-49 years (odds ratio [OR], 12.4; 95% confidence interval [CI], 8.8-18.9), female sex (OR, 3.3; 95% CI, 2.6-4.1), high school or lower education (OR, 1.7; 95% CI, 1.3-2.1), hepatitis C seropositivity (OR, 25.0; 95% CI, 17.5-35.8), and first-time blood donation (OR, 3.6; 95% CI, 2.8-4.7). HTLV-II seroprevalence was highest at the two West Coast blood centers. These data are consistent with a 30-year-old epidemic of HTLV-II in the United States due to injection drug use and secondary sexual transmission and with an apparent West Coast focus.